Semnur Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	152.97	2.98	1.64	1.65
Research & Development	2.07	1.71	1.62	2.12
Operating Expenses	155.03	4.69	3.26	3.77
Operating Income	-155.03	-4.69	-3.26	-3.77
Pretax Income	-155.03	-4.69	-3.26	-3.77
Net Income	-155.03	-4.69	-3.26	-3.77
Net Income to Common	-155.03	-4.69	-3.26	-3.77
Shares Outstanding (Basic)	160	160	160	160
Shares Outstanding (Diluted)	160	160	160	160
EPS (Basic)	-0.97	-0.03	-0.02	-0.02
EPS (Diluted)	-0.97	-0.03	-0.02	-0.02
EBIT	-155.03	-4.69	-3.26	-3.77

Source: S&P Global Market Intelligence. Standard template. Financial Sources.